Other languages CorMedix Inc.

Equities

CRMD

US21900C3088

Real-time Estimate Cboe BZX Other stock markets 02:32:57 2024-05-17 pm EDT			5-day change	1st Jan Change
5.1 ^USD	-1.92%		-1.12%	+35.96%

May. 09	Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	Apr. 15
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization	Apr. 08
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC	Apr. 08
Sector Update: Health Care Stocks Ease Wednesday Afternoon	Mar. 13
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says	Mar. 13
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath	Jan. 30
Cormedix Inc. Announces Commercial and Operational Updates	Jan. 08
CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts	Dec. 15
CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023	Dec. 15
CorMedix Inc. Announces Partnership with The Leapfrog Group	Dec. 04
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 15
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Nov. 15
Sector Update: Health Care	Nov. 15
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients	Nov. 15
CorMedix's DefenCath Approved by US FDA; Shares Jump	Nov. 15
U.S. FDA approves CorMedix's antimicrobial drug	Nov. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CorMedix Inc.

Equities

CRMD

US21900C3088

Other languages

Filters